PRESS RELEASES

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL ERYTECH invited by FDA to request a pre-BLA meeting F irst step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the
View HTML
Toggle Summary ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
ERYTECH Announces Completion of First Cohort i n a Phase 1 Investigator Sponsored Trial of Eryaspase in First -Line Pancreatic Cancer No d ose -l imiting t oxicity reported in the first dose cohor t Encouraging clinical activity observed in first patients Trial will be escalated to the next dose
View HTML
Toggle Summary ERYTECH to Participate in Upcoming Virtual Investor Conferences in April
ERYTECH to Participate in Upcoming Virtual Investor Conferences in April Lyon (France) and Cambridge, MA (U.S.), April 7, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2021
                                                                                    Monthly information related to total number of voting rights and shares composing the share capital – March 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021
                                                                                   Monthly information related to total number of voting rights and shares composing the share capital – February 28, 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
View HTML
Toggle Summary ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update
ERYTECH to Host Fourth Quarter and Full Year 2020 Conference Call and Business Update Lyon (France) and Cambridge, MA (U.S.), March 4, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug
View HTML
Toggle Summary ERYTECH to Participate in Upcoming Virtual Investor Conferences in March
ERYTECH to Participate in Upcoming Virtual Investor Conferences in March Lyon (France) and Cambridge, MA (U.S.), February 24, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances
View HTML
Toggle Summary ERYTECH to Present at the 2021 BIO CEO & Investor Conference
ERYTECH to Present at the 2021 BIO CEO & Investor Conference Lyon (France) and Cambridge, MA (U.S.), February 10, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood
View HTML
Toggle Summary ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis
ERYTECH Announces TRYbeCA-1 Phase 3 Trial in 2L Pancreatic Cancer to Continue to Final Analysis                                                         The Independent Data Monitoring Committee (IDMC) recommends trial to continue to final analysis, expected in Q4 2021 No safety issues identified,
View HTML
Toggle Summary Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021
                                                                                    Monthly information related to total number of voting rights and shares composing the share capital – January 31, 2021. Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
View HTML
Top